Studier BMT-gruppen

Decidua stromaceller vid steroidresistent akut GvHD

A multicenter, open-label, randomized, phase I/II clinical trial comparing safety and durable overall response rate (DOR) at 56 days in patients with steroid resistant severe acute GvHD after allogeneic hematopoietic stem cell transplantation treated with decidua stromal cells (DSC) or best available treatment (BAT).

DSC Protocol v 5.0 2022-06-21